IP Library Granted Patent US 6,936,637
Granted Patent B2
US 6,936,637 · App. 10/263,402 · Granted Aug 30, 2005

Prevention of apoptosis in non-cancerous cells

Assignee: University of Tennessee Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,936,637
App. No.
10/263,402
Granted
Aug 30, 2005
Kind
B2
Abstract

Treatment of normal, non-cancerous, animal cells with an agent that depletes polyamines within the cells results in an inhibition of apoptosis when the cells are exposed to an inducer of apoptosis. This inhibition of apoptosis is not observed, or is observed to a lesser extent, in similarly treated cancerous cells. The method of the invention is useful in obtaining preferential killing of cancer cells, as opposed to normal cells, due to anti-cancer therapy.

Claims (8)

1. A method for inhibiting apoptosis in non-cancerous intestinal cells in a patient that is to be treated by an antineoplastic therapeutic agent for a neoplastic condition, which non-cancerous cells are susceptible to apoptosis due to the antineoplastic therapeutic agent, comprising administering to the patient an effective amount of a first agent that results in the depletion of polyamines within the non-cancerous cells, depleting the polyamines in the non-cancerous cells of the patient, and administering to the patient a second agent which is an antineoplastic therapeutic agent, thereby inhibiting apoptosis in the non-cancerous intestinal cells due to the treatment with the antineoplastic therapeutic agent.

2. The method of claim 1 wherein the patient is a human patient.

3. The method of claim 1 wherein the patient is a non-human animal.

4. The method of claim 1 wherein the antineoplastic therapeutic agent is radiation therapy.

5. The method of claim 4 wherein the radiation therapy is by x-ray or gamma irradiation.

6. The method of claim 4 wherein said first agent is DL-œ-difluoromethylornithine.

7. The method of claim 1 wherein the antineoplastic therapeutic agent is a chemical agent.

8. The method of claim 7 wherein said first agent is DL-œ-difluoromethylornithine.

Assignments (1)
CHANGE OF NAME Recorded Nov 22, 2004
From: UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE
To: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Reel/Frame 015394/0687 →
Continuity (3)
Continuation 0964976300 · Aug 28, 2000
Provisional Application 6015152800 · Aug 30, 1999
Related Publication 20030027866A1 · Feb 6, 2003